C9orf85

Across TCGA pan-cancer cohorts, C9orf85 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated C9orf85 data layer compared with 22 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher C9orf85 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated C9orf85 expression acts as an unfavorable survival marker.

KIRP, COAD, and CHOL are the cancer types where C9orf85 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	All	0.270	0.904	<.001	12	view →
COAD	DFS	Median	All	0.113	0.559	.005	4	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

C9orf85–KIRP (OS)

Open the KIRP breakdown →